Rempex Pharmaceuticals, Inc.

Metabasis Therapeutics, Inc.

Qpex Biopharma, Inc.

Melinta Subsidiary Corp.

Schering-plough Animal Health Corporation

Relypsa, Inc.

Essential Therapeutics, Inc.

Intervet Inc.

Trine Pharmaceuticals, Inc.

Schering-plough Corporation

Melinta Therapeutics, Inc.

Scott J Hecker

Raja K Reddy

Serge H Boyer

Tomasz W Glinka

Maxim Totrov

Michael N Dudley

David C Griffith

Olga Rodny

Gavin C Hirst

Zhili Sun

Venkat Reddy Mali

Qun Dang

Robert Huerta Lemus

Haiqing Li

Jorge E Gomez-Galeno

Matthew P Grote

Thanh Huu Nguyen

K Raja Reddy

Brett C Bookser

Paul D Van Poelje

William Craigo

Mingwei Chen

Mark D Erion

Nicholas Brian Raffaele

Jeff Stebbins

Mali Venkat Reddy

YongQi Mu

Paul Mansky

Eric F Connor

Michael James Cope

Kalpesh N Biyani

Olga Lomovskaya

Jun Shao

David E Bergbreiter

Deidre Madsen

Faleh Salaymeh

Angela Lee

Elizabeth Goka

Dale Edward Shuster

Hongmin Zhang

Inez Lees

Rajeshwar Singh

Ving J Lee

Constantine G Boojamra

Zhuoyi Su

Jordan Kopping

Grace Huynh

Sunil V Pansare

Yongqi Mu

Serge Henri Boyer

Grace Quaker

David Bernard Smith

Aesop Cho

Brian Walter Eastman

Lee Shun Chong

Robert Higuchi

Laurent Lefort

Andreas H M De Vries

Hubertus J A Dielemans

Angela Gonzalez De Castro

Grace May

Xinnan Zhang

Trevor Calkins

Roger L&eacute;ger

R&eacute;my C Lemoine

Petrus J Hermsen

Gerardus K M Verzijl

Felah Salaymeh

Jordon Kopping

Hubertus JA Dielemans

Paul D Van Polje

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.

Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives

Compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility, are disclosed. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation.

Tetracycline compositions

Disclosed herein are antimicrobial compounds, compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use a therapeutic agents.

Boronic acid derivatives and therapeutic uses thereof

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, β-lactamase inhibitors (BLIs).

Disclosed herein are methods for the preparation of boronate derivatives in the synthesis of antimicrobial compounds and uses thereof. Disclosed herein includes method of making a compound of Formula (B) by reducing the ketone group of the keto-ester compound of Formula (A), and the reduction can be performed using a Ruthenium based catalyst system or using an alcohol dehydrogenase bioreduction system.

Synthesis of boronate ester derivatives and uses thereof

The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation.

Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or Co-crystals and prodrugs thereof. Formula I 

Glucagon antagonists

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, &#x3b2;-lactamase inhibitors (BLIs).

Boronic acid derivatives and synthesis thereof

The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof and pharmaceutical compositions comprising the same.

Antagonists of the glucagon receptor

This invention pertains to the use of fused bicycle heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.

Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof

Disclosed herein are boronate intermediates in the synthesis of antimicrobial compounds and the use and preparation thereof. Some embodiments relate to crystalline boronate salt derivatives and their use in the synthesis of therapeutic compounds.

Synthesis of boronate salts and uses thereof

Disclosed herein are antimicrobial compounds, compositions, pharmaceutical compositions, and the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.

Cyclic boronic acid ester derivatives and therapeutic uses thereof

Growing community of inventors

Del Mar, CA, United States of America

Scott J Hecker